Mantle cell lymphoma (MCL) is an infrequent subtype of non-Hodgkin's lymphoma (NHL) and represents between 4-8% of adult lymphomas. Recently an increase in its incidence to 1-2 cases/100,000 inhabitants/year has been observed. The first line of treatment is based on chemoimmunotherapy and depends on age and the initial stage at diagnosis. There are no second line or successive treatments. There are currently several drugs available that provide acceptable results.
CITATION STYLE
Herrero-Vicent, C., Machado, I., Illueca, C., Avaria, A., Salazar, C., Hernandez, A., … Lavernia, J. (2016). Diagnostic and therapeutic update of mantle cell lymphoma (MCL): Analysis of seven cases treated in a centre in one year. Ecancermedicalscience, 10. https://doi.org/10.3332/ecancer.2016.627
Mendeley helps you to discover research relevant for your work.